首頁 > 市場調查報告書 > 製藥

感染疾病

甲癬治療市場規模、佔有率及成長分析（按類型、通路、治療方法和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1897253

甲癬治療市場規模、佔有率及成長分析（按類型、通路、治療方法和地區分類）－2026-2033年產業預測

Onychomycosis Treatment Market Size, Share, and Growth Analysis, By Type (Distal Subungual Onychomycosis, Candida Onychomycosis), By Distribution Channel, By Treatment Type, By Region-Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 208 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，甲癬治療市場規模將達到 53.3 億美元，到 2025 年將達到 57.9 億美元，到 2033 年將達到 112 億美元，預測期（2026-2033 年）的複合年成長率為 8.6%。

灰指甲治療市場專注於採用各種治療方法治療真菌性感染疾病，包括外用藥物、雷射治療和口服抗真菌藥物。灰指甲病例的增加、治療方法選擇的增加以及公眾意識的提高是推動市場成長的關鍵因素。此外，醫療保健支出的成長也使得更多患者能夠獲得先進的治療方法。然而，高昂的治療費用和潛在的副作用對市場成長構成挑戰。許多先進的治療方法，例如雷射治療和口服藥物，價格昂貴且可能有風險，例如肝損傷和胃腸道不適，這導致患者不願接受治療。儘管如此，藥物研發領域的創新，例如基於奈米技術的藥物遞送系統、緩釋性和有效的外用療法的進步，預計將推動市場成長。

甲癬治療的促進因素

人口老化、糖尿病盛行率上升以及免疫功能低下患者數量的增加正在推動灰指甲治療市場的成長。此外，患者對該疾病的認知不斷提高，加上診斷能力的提升以及醫療專業人員對先進治療方法的了解不斷加深，導致確診病例數量激增。隨著患者和醫療服務提供者都在尋求更好的方法來應對這種常見疾病，人們對甲癬的認知和了解不斷加深，對有效治療方法的需求也顯著成長。因此，這些相互關聯的因素正在推動市場顯著成長。

甲癬治療市場的限制因素

目前可用於治療灰指甲的各種療法可能並非對所有患者都完全有效，並且可能增加症狀復發的風險。這些療法的療效可能因真菌感染疾病的特定類型和嚴重程度而異，這凸顯了該領域持續研究和開發的重要性。由於患者對治療的反應各不相同，因此人們越來越需要能夠滿足甲癬患者多樣化需求的創新解決方案。克服這些限制對於推進治療方案的開發和改善患者預後至關重要。

甲癬治療市場趨勢

先進雷射療法的引入，特別是二氧化碳 (CO2) 雷射和藍光雷射，已成為甲癬治療市場的一大趨勢。 CO2 雷射因其能夠深入甲組織，有效靶向頑固真菌感染疾病而廣受歡迎。這項技術是對傳統治療方法的補充，並因其精準性和有效性而備受青睞。同時，藍光雷射已成為治療輕度感染疾病或與其他治療方法合併輔助性治療的可行選擇。這項利用熱能對抗真菌的技術，反映了灰指甲治療領域對微創高效解決方案日益成長的需求。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭格局

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市集活動
主要企業市佔率（2025 年）

主要企業簡介

Teva Pharmaceutical Industries Ltd.（Israel）
Sanofi SA（France）
Medimetriks Pharmaceuticals, Inc.（US）
Galderma（Switzerland）
Johnson & Johnson（US）
Novartis AG（Switzerland）
Moberg Pharma AB（Sweden）
Cardinal Health, Inc.（US）
Pfizer Inc.（US）
Almirall, SA（Spain）
Bayer AG（Germany）
Viatris Inc.（US）
GlaxoSmithKline plc（UK）
Cipla Ltd.（India）
Dr. Reddy's Laboratories Ltd.（India）
Evofem Biosciences, Inc.（US）
Nabriva Therapeutics plc（Ireland）
Kaken Pharmaceutical Co., Ltd.（Japan）
Hikma Pharmaceuticals PLC（UK）
Dermavant Sciences, Inc.（US）
Sientra, Inc.（US）
Zynerba Pharmaceuticals, Inc.（US）

簡介目錄

Product Code: SQMIG35H2265

Onychomycosis Treatment Market size was valued at USD 5.33 Billion in 2024 and is poised to grow from USD 5.79 Billion in 2025 to USD 11.2 Billion by 2033, growing at a CAGR of 8.6% during the forecast period (2026-2033).

The onychomycosis treatment market focuses on addressing nail fungal infections through various modalities, including topical solutions, laser therapies, and oral antifungal medications. A rise in onychomycosis cases, enhanced treatment options, and increased awareness are key drivers of market expansion. Additionally, rising healthcare expenditures enable broader access to advanced therapies. However, high treatment costs and potential side effects present challenges to market growth, as many advanced options, such as laser therapies and oral medications, can be prohibitively expensive and may pose risks like liver damage or gastrointestinal issues, causing patient reluctance. Nonetheless, the market is poised for growth through innovations in drug development, including advancements in drug delivery systems utilizing nanotechnology, sustained-release formulations, and effective topical treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Onychomycosis Treatment Market Segments Analysis

Global Onychomycosis Treatment Market is segmented by Treatment Type, Disease Indication, Age Group, Gender, Distribution Channel, and region. Based on Treatment Type, the market is segmented into Drugs, Lasers, and Photodynamic Therapy. Based on Disease Indication, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis, and Total Dystrophic Onychomycosis. Based on Age Group, the market is segmented into 0 to 18 Years, 19 to 39 Years, 40 to 64 Years, and 65 Years & Above. Based on Gender, the market is segmented into Male, and Female. Based on Distribution Channel, the market is segmented into Institutional Sales, and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Onychomycosis Treatment Market

The expanding incidence of fungal nail infections driven by an aging population, rising diabetes prevalence, and an increase in immune-compromising conditions is propelling the onychomycosis treatment market. Additionally, heightened awareness about the condition among patients, coupled with improved diagnostic capabilities and advanced treatment options recognized by healthcare professionals, is leading to a surge in diagnoses. This growing recognition and understanding of onychomycosis are significantly contributing to the demand for effective treatments, as both patients and providers seek better solutions for managing this prevalent condition. As a result, the market is witnessing substantial growth driven by these interrelated factors.

Restraints in the Onychomycosis Treatment Market

Currently, various treatments available for Onychomycosis may not provide adequate effectiveness for every patient, leading to a higher likelihood of recurrence of the condition. The efficacy of these treatments can vary based on the specific type and severity of the fungal infection, highlighting the importance of ongoing research and development in this area. As different patients respond uniquely to treatments, there is an increasing demand for innovative solutions that can cater to the diverse needs of those affected by Onychomycosis. Addressing these limitations is crucial for advancing treatment options and improving patient outcomes.

Market Trends of the Onychomycosis Treatment Market

The Onychomycosis Treatment market is witnessing a notable trend toward advanced laser therapies, particularly the adoption of Carbon Dioxide (CO2) and Blue Light lasers. CO2 lasers are gaining prominence due to their ability to deeply penetrate nail tissues, effectively targeting stubborn fungal infections. This technology is complementing traditional treatments and is preferred for its precision and efficacy. Meanwhile, Blue Light lasers are emerging as a viable option for milder infections or as an adjunct to other therapeutic modalities, harnessing heat energy to combat fungi. This shift towards innovative laser treatments reflects a growing demand for less invasive, effective solutions in the nail fungus treatment segment.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
PESTEL Analysis
Top Investment Analysis
Key Success Factor
Degree of Competition

Onychomycosis Treatment Market by Treatment Type

Market Overview
Drugs
- Oral
- RX
- OTC
- Tropical
- RX
- OTC
Lasers
- C02 Ablative Lasers
- Nd: YAG Lasers
- Dual-wavelength near-infrared Lasers
Photodynamic Therapy

Onychomycosis Treatment Market by Disease Indication

Market Overview
Distal Subungual Onychomycosis
White Superficial Onychomycosis
Proximal Subungual Onychomycosis
Candidal Onychomycosis
Total Dystrophic Onychomycosis

Onychomycosis Treatment Market by Age Group

Market Overview
0 to 18 Years
19 to 39 Years
40 to 64 Years
65 Years & Above

Onychomycosis Treatment Market by Gender

Market Overview
Male
Female

Onychomycosis Treatment Market by Distribution Channel

Market Overview
Institutional Sales
- Hospitals
- Dermatology Clinics
Retail Sales
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies & Online Sales

Onychomycosis Treatment Market Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2025

Key Company Profiles

Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medimetriks Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galderma (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moberg Pharma AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almirall, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dr. Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evofem Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nabriva Therapeutics plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kaken Pharmaceutical Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dermavant Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sientra, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zynerba Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments